Holen Sie sich die Stockscreener-App
1.17
2.63%
0.03
Vorhandelsmarkt:
1.21
0.04
+3.42%
Schlusskurs vom Vortag:
$1.14
Offen:
$1.16
24-Stunden-Volumen:
7.39M
Relative Volume:
0.70
Marktkapitalisierung:
$320.42M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-0.78
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-7.87%
1M Leistung:
-10.00%
6M Leistung:
-35.00%
1J Leistung:
-25.00%
1-Tages-Spanne:
$1.15
$1.2199
1-Wochen-Bereich:
$1.13
$1.27
52-Wochen-Spanne:
$1.08
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.17 | 320.42M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner - marketscreener.com
PacBio partners with global Alzheimer’s initiative By Investing.com - Investing.com India
PacBio partners with global Alzheimer’s initiative - Investing.com Australia
PacBio (PACB) Joins DAC's North African Dementia Project | PACB Stock News - GuruFocus
PacBio Partners with Davos Alzheimer’s Collaborative to Advance Alzheimer's Research in North Africa - Nasdaq
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
Positive week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional investors who lost 57% over the past year - Yahoo
Pacific Biosciences of California jumps 22% after prelim Q1 results, guides FY - MSN
Canaccord maintains $3 price target on PACB, reiterates Buy By Investing.com - Investing.com South Africa
Tariffs, NIH ‘uncertainty’ force PacBio into layoffsSan Francisco Business Times - The Business Journals
Canaccord maintains $3 price target on PACB, reiterates Buy - Investing.com
PacBio outlines cost-cutting, revenue meets Q1 target By Investing.com - Investing.com South Africa
PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - Reuters
Healthcare Stocks Ride a Tariffs-Relief Wave -- Healthcare Roundup - MarketScreener
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - The Globe and Mail
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs - Benzinga
Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On Wednesday - Benzinga
Pacific Biosciences of California Sees Lower Q1 Revenue, Plans Job Cuts to Reduce Costs - MarketScreener
PacBio Q1 Prel. Revenue Down, Says Met Expectations; To Cut Jobs - Nasdaq
PacBio outlines cost-cutting, revenue meets Q1 target - Investing.com
Pacbio posts Preliminary Q1 2025 Revenue And Reiterates 2025 Revenue Guidance - marketscreener.com
Pacific Biosciences of California, Inc. Reiterates Earnings Guidance for the Full Year 2025 - marketscreener.com
PacBio's Bold Move: $50M Cost Cut Plan as Q1 Shows Record Consumables Growth - Stock Titan
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million - Yahoo Finance
PacBio Strengthens Leadership: New CFO Joins with Strategic Equity Package - Stock Titan
Customer success story: The University of Bern takes long-read sequencing to the next level with SPRQ chemistry - PacBio
Pacific Biosciences of California appoints CFO - MSN
PACB stock touches 52-week low at $1.15 amid market challenges - Investing.com
PacBio names Jim Gibson as new CFO By Investing.com - Investing.com South Africa
Pacific Biosciences of California Names Jim Gibson CFO - Marketscreener.com
PacBio names Jim Gibson as new CFO - Investing.com
Jim Gibson To Join PacBio As Chief Financial Officer - MarketScreener
Jim Gibson to join PacBio as Chief Financial Officer - GlobeNewswire
Tech Giant CFO Who Raised $1B+ Joins PacBio: Ex-Tesla, Apple Executive to Drive Growth - Stock Titan
Publications March 2025 - Pacific Biosciences
Assessing Pacific Biosciences: Insights From 6 Financial Analysts - Benzinga
ATTENTION PACB SHAREHOLDERS: Investors Who Lost Money on Pacific Biosciences of California, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
Here's Why You Should Retain PacBio Stock in Your Portfolio Now - MSN
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - MSN
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
PacBio, Take2 Resolve DNA Sequencing Patent Infringement Dispute - Bloomberg Law News
Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading? - Insider Monkey
10 Most Volatile Stocks Under $3 For Day Trading - Insider Monkey
Inspiring the next generation of scientists: How multidisciplinary science powers PacBio technology - Pacific Biosciences
Cantor Fitzgerald maintains PACB overweight rating, $2.50 target - Investing.com
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks - The Globe and Mail
Pacific Biosciences of California Inc. (PACB) reports earnings - qz.com
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):